Latest Competition News

My Rewards International Limited has completed its acquisition of Fly Wallet, a Mastercard principal member specialising in white label loyalty wallet solutions, in a $785,000 deal combining shares and cash installments.

Oliver’s Real Food reported an 18% revenue decline in the March 2025 quarter, impacted by store closures and trading calendar shifts, yet achieved a strong rebound in EBITDA margin to 11.5%.

Harmoney Corp upgrades its FY25 cash NPAT guidance to $5.5 million, driven by strong loan book growth and improved margins, while announcing a strategic 5% on-market share buy-back.

Way2VAT Ltd reported a robust 54% increase in Q1 FY25 revenue to A$1.05 million, driven by new client onboarding and higher VAT claim volumes, alongside strategic cost reductions and fresh credit facilities.

GreenHy2 Limited reports a strategic push in Europe with new contracts for its advanced supercapacitor and hydrogen storage technologies, alongside a cash position of $814K and four quarters of funding runway.

Syrah Resources reports a strategic pause at its Balama graphite mine while advancing production at its Vidalia AAM facility, navigating evolving US trade policies and strong EV-driven demand. The company’s integrated ex-China supply chain and ESG credentials position it for growth despite near-term operational headwinds.

Syrah Resources halts production at its Balama graphite mine amid ongoing protests while advancing its US-based Vidalia anode material facility, securing a significant $165 million US tax credit and forging key offtake deals.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Core Lithium Ltd progresses its Finniss Lithium Project Restart Study, securing full ownership of site infrastructure and reporting promising gold exploration results at Shoobridge.

Donaco International reported a modest revenue and EBITDA decline in Q3 FY2025 but strengthened its cash reserves. Meanwhile, the company agreed to a full acquisition scheme at a significant premium, setting the stage for shareholder decisions amid regulatory uncertainties.

Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.